GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ProKidney Corp (NAS:PROK) » Definitions » EV-to-EBIT

ProKidney (ProKidney) EV-to-EBIT : 1.48 (As of May. 11, 2024)


View and export this data going back to 2022. Start your Free Trial

What is ProKidney EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, ProKidney's Enterprise Value is $-191.70 Mil. ProKidney's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-129.44 Mil. Therefore, ProKidney's EV-to-EBIT for today is 1.48.

The historical rank and industry rank for ProKidney's EV-to-EBIT or its related term are showing as below:

PROK' s EV-to-EBIT Range Over the Past 10 Years
Min: -10.61   Med: 0   Max: 2.74
Current: 1.48

During the past 4 years, the highest EV-to-EBIT of ProKidney was 2.74. The lowest was -10.61. And the median was 0.00.

PROK's EV-to-EBIT is ranked better than
62.12% of 433 companies
in the Biotechnology industry
Industry Median: 9.43 vs PROK: 1.48

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. ProKidney's Enterprise Value for the quarter that ended in Dec. 2023 was $1,242.78 Mil. ProKidney's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-129.44 Mil. ProKidney's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -10.42%.


ProKidney EV-to-EBIT Historical Data

The historical data trend for ProKidney's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ProKidney EV-to-EBIT Chart

ProKidney Annual Data
Trend Dec20 Dec21 Dec22 Dec23
EV-to-EBIT
- - -10.45 -9.60

ProKidney Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -10.45 -19.96 -15.67 -10.34 -9.60

Competitive Comparison of ProKidney's EV-to-EBIT

For the Biotechnology subindustry, ProKidney's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ProKidney's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ProKidney's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where ProKidney's EV-to-EBIT falls into.



ProKidney EV-to-EBIT Calculation

ProKidney's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=-191.697/-129.439
=1.48

ProKidney's current Enterprise Value is $-191.70 Mil.
ProKidney's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-129.44 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


ProKidney  (NAS:PROK) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

ProKidney's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2023 ) =EBIT / Enterprise Value (Q: Dec. 2023 )
=-129.439/1242.781934
=-10.42 %

ProKidney's Enterprise Value for the quarter that ended in Dec. 2023 was $1,242.78 Mil.
ProKidney's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-129.44 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


ProKidney EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of ProKidney's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


ProKidney (ProKidney) Business Description

Traded in Other Exchanges
Address
2000 Frontis Plaza Boulevard, Suite 250, Winston-Salem, NC, USA, 27103
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's own cells isolated from the patient intended for treatment. Its lead product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's own renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease.
Executives
Chamath Palihapitiya 10 percent owner THE SOCIAL-CAPITAL PARTNERSHIP, L.L.C., 506 SANTA CRUZ AVENUE, SUITE 300, MENLO PARK CA 94025
Sc Pipe Holdings Llc 10 percent owner 506 SANTA CRUZ AVE., SUITE 300, MENLO PARK CA 94025
Sc Master Holdings, Llc 10 percent owner 506 SANTA CRUZ AVENUE, SUITE 300, MENLO PARK CA 94025
Bruce Culleton officer: EVP, Clinical Development 2000 FRONTIS PLAZA BLVD., SUITE 250, WINSTON-SALEM NC 27103
Aaron Cowen 10 percent owner 540 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Mary Weger officer: Chief People Officer ONE MAIN STREET, SUITE 800, CAMBRIDGE MA 02142
William F Doyle director
Tolerantia, Llc 10 percent owner 110 EAST 59TH STREET, SUITE 3300, NEW YORK NY 10022
Jimenez Santos Jose Ignacio director C/O PROKIDNEY CORP., 3929 WESTPOINT BLVD., SUITE G, WINSTON-SALEM NC 27103
Deepak Jain officer: Chief Operating Officer C/O PROKIDNEY CORP., 3929 WESTPOINT BLVD., SUITE G, WINSTON-SALEM NC 27103
Darin J. Weber officer: SVP of Regulatory Development C/O PROKIDNEY CORP., 3929 WESTPOINT BLVD., SUITE G, WINSTON-SALEM NC 27103
Libbie Parker Mckenzie officer: Chief Medical Officer C/O PROKIDNEY CORP., 3929 WESTPOINT BLVD., SUITE G, WINSTON-SALEM NC 27103
James Coulston officer: Chief Financial Officer C/O PROKIDNEY CORP., 3929 WESTPOINT BLVD., SUITE G, WINSTON-SALEM NC 27103
Jennifer A. Fox director C/O NUVATION BIO INC., 1500 BROADWAY, SUITE 1401, NEW YORK NY 10036
Timothy Bertram director, officer: Chief Executive Officer C/O TENGION, INC., 2900 POTSHOP LANE, SUITE 100, EAST NORRITON PA 19403